loading page

Epicutaneous Immunotherapy for the Treatment of Peanut Allergy
  • +3
  • M. Ravindran,
  • Hugh Sampson,
  • Edwin Kim,
  • Katharine Bee,
  • Todd Green,
  • A. Wesley Burks
M. Ravindran
The University of North Carolina at Chapel Hill School of Medicine
Author Profile
Hugh Sampson
Icahn School of Medicine at Mount Sinai Department of Pediatrics
Author Profile
Edwin Kim
The University of North Carolina at Chapel Hill School of Medicine
Author Profile
Katharine Bee
DBV Technologies
Author Profile
Todd Green
DBV Technologies
Author Profile
A. Wesley Burks
The University of North Carolina at Chapel Hill School of Medicine

Corresponding Author:wburks@email.unc.edu

Author Profile

Abstract

Peanut allergy treatment options remain limited, but novel approaches are being studied, including epicutaneous immunotherapy (EPIT). EPIT uses the cutaneous immune system to promote tolerance to food allergens. Viaskin TM Peanut, an approach to EPIT in late-stage clinical development uses an occlusive patch with a condensation chamber that enables natural epidermal water loss to solubilize dry antigen on the patch, which is then absorbed and captured by skin dendritic cells. This form of EPIT does not require disruption of the skin barrier, thus avoiding a proinflammatory cytokine response by targeting the non-vascularized epidermis and limiting systemic allergen exposure. Extensive preclinical research suggests that Viaskin Peanut has a distinct mechanism of desensitization, including the potential for disease modification, driven by a unique population of regulatory T cells. Numerous clinical studies of Viaskin Peanut have demonstrated desensitization and reductions in reaction severity, particularly in children aged 1 through 11 years, as well as a favorable safety profile with mostly mild to moderate skin reactions that were observed to decrease over time. EPIT with Viaskin Peanut may be a potential therapeutic option for peanut allergy that is clinically practical with long-term efficacy and tolerability.
17 Apr 2024Submitted to Allergy
17 Apr 2024Review(s) Completed, Editorial Evaluation Pending
20 Apr 2024Reviewer(s) Assigned
08 May 2024Editorial Decision: Revise Minor
05 Aug 20241st Revision Received
20 Aug 2024Assigned to Editor
20 Aug 2024Submission Checks Completed
20 Aug 2024Review(s) Completed, Editorial Evaluation Pending
22 Aug 2024Reviewer(s) Assigned
11 Sep 2024Editorial Decision: Accept